NYTNYT·2hBusiness
score-0.25
Novo Nordisk CEO Mike Doustdar Says Investors Underestimate Promise of Company’s Drugs in Year One of Turnaround
Original
Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future
“Headline emphasizes investor anxiety and uncertainty, while the summary offers a defensive counter-narrative of underestimated promise.”